Literature DB >> 15377746

Fluvoxamine treatment of major depression associated with multiple sclerosis.

Francesco Benedetti1, Euridice Campori, Cristina Colombo, Enrico Smeraldi.   

Abstract

Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15377746     DOI： 10.1176/jnp.16.3.364

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  10 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Authors:  Antonios Bayas; Katrin Schuh; Monika Baier; Stefan Viktor Vormfelde
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

3.  Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions.

Authors:  Adrianna Ratajska; Jonathan Zurawski; Brian Healy; Bonnie I Glanz
Journal:  Int J MS Care       Date:  2019 May-Jun

4.  A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis.

Authors:  Theodore R Brown; April Slee
Journal:  Int J MS Care       Date:  2015 Mar-Apr

Review 5.  Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis.

Authors:  Richard M Sobel; Susan Lotkowski; Steven Mandel
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

6.  Mood-congruent negative thinking styles and cognitive vulnerability in depressed COVID-19 survivors: A comparison with major depressive disorder.

Authors:  Francesco Benedetti; Mariagrazia Palladini; Greta D'Orsi; Roberto Furlan; Fabio Ciceri; Patrizia Rovere-Querini; Mario Gennaro Mazza
Journal:  J Affect Disord       Date:  2022-04-20       Impact factor: 6.533

7.  Emotional change-associated T cell mobilization at the early stage of a mouse model of multiple sclerosis.

Authors:  Giuseppa Piras; Lorenza Rattazzi; Adam McDermott; Robert Deacon; Fulvio D'Acquisto
Journal:  Front Immunol       Date:  2013-11-21       Impact factor: 7.561

8.  Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study.

Authors:  Nikolay N Yahno; Anastasia V Fedotova
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-02       Impact factor: 2.570

9.  Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis.

Authors:  Majid Ghareghani; Kazem Zibara; Heibatollah Sadeghi; Shima Dokoohaki; Hossein Sadeghi; Roya Aryanpour; Amir Ghanbari
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

10.  Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations.

Authors:  Maria Skokou; Evanthia Soubasi; Philippos Gourzis
Journal:  ISRN Neurol       Date:  2012-10-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.